Cargando…

Corrigendum to: A new therapy for Transthyretin amyloidosis, no longer an orphan condition

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286843/ https://www.ncbi.nlm.nih.gov/pubmed/34285681 http://dx.doi.org/10.1093/eurheartj/suab065

Ejemplares similares

A new therapy for transthyretin amyloidosis, no longer an orphan condition
por: Quarta, Candida Cristina, et al.
Publicado: (2020)

CORRIGENDUM: Utility of (99 m)Tc-Pyrophosphate Scintigraphy in Diagnosing Transthyretin Cardiac Amyloidosis in Real-World Practice
por: Tsutsui, Yoshitomo, et al.
Publicado: (2019)

Corrigendum to “Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births”
por: Kroese, S. J., et al.
Publicado: (2022)

Recent advances in transthyretin amyloidosis therapy
por: Ueda, Mitsuharu, et al.
Publicado: (2014)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Corrigendum to “New and Emerging Therapies for Osteoporosis”
por: Lewiecki, E. Michael, et al.
Publicado: (2017)

Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis
por: Donnellan, Eoin, et al.
Publicado: (2020)

An autoregulatory loop controlling orphan nuclear receptor DAX-1 gene expression by orphan nuclear receptor ERRγ
por: Park, Yun-Yong, et al.
Publicado: (2018)

Corrigendum to: Adaptation of the in vitro micronucleus assay for genotoxicity testing using 3D liver models supporting longer-term exposure durations
por: Conway, Gillian E, et al.
Publicado: (2021)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Multidisciplinary Approaches for Transthyretin Amyloidosis
por: Koike, Haruki, et al.
Publicado: (2021)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

Contributions of Animal Models to the Mechanisms and Therapies of Transthyretin Amyloidosis
por: Ibrahim, Ridwan Babatunde, et al.
Publicado: (2019)

Accessibility to Occupational Therapy Services for Hereditary Transthyretin Amyloidosis
por: Gayà-Barroso, Aina, et al.
Publicado: (2022)

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
por: Mathew, Veena, et al.
Publicado: (2019)

EGCG-Mediated Protection of Transthyretin Amyloidosis by Stabilizing Transthyretin Tetramers and Disrupting Transthyretin Aggregates
por: Zou, Huizhen, et al.
Publicado: (2023)

A Late Diagnosis of Transthyretin Amyloidosis
por: Pfirman, Kristopher S, et al.
Publicado: (2022)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Campbell, Courtney M., et al.
Publicado: (2022)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
por: Yamaguchi, Hiroki, et al.
Publicado: (2022)

Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
por: Maestro‐Benedicto, Alba, et al.
Publicado: (2022)

Corrigendum to “Sleep-Disordered Breathing in Patients with Heart Failure: New Trends in Therapy”
por: Kazimierczak, Anna, et al.
Publicado: (2015)

Screening for hereditary transthyretin amyloidosis in Bulgaria
por: Nakov, Radislav, et al.
Publicado: (2021)

Molecular Tweezers Targeting Transthyretin Amyloidosis
por: Ferreira, Nelson, et al.
Publicado: (2014)

Evolving landscape in the management of transthyretin amyloidosis
por: Hawkins, Philip N., et al.
Publicado: (2015)

Modulation of the Mechanisms Driving Transthyretin Amyloidosis
por: Bezerra, Filipa, et al.
Publicado: (2020)

Transthyretin Cardiac Amyloidosis: Underrecognized in the Underrepresented
por: Leedy, Douglas J., et al.
Publicado: (2023)

Corrigendum to “Physiologic Conditions Affect Toxicity of Ingested Industrial Fluoride”
por: Sauerheber, Richard
Publicado: (2017)

Corrigendum to “Cell therapies in ovarian cancer”
Publicado: (2021)

Corrigendum to “New Issues in the Management of Osteoporosis”
por: Sirola, Joonas, et al.
Publicado: (2017)

Hereditary transthyretin amyloidosis: a case report
por: Lee, Angela, et al.
Publicado: (2022)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Corrigendum to a new oral testosterone undecanoate (TU) therapy comes of age for the treatment of hypogonadal men
Publicado: (2021)

Corrigendum: Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis
por: Vilas-Boas, Maria do Carmo, et al.
Publicado: (2022)

Improving attitudes toward electroconvulsive therapy – CORRIGENDUM
por: Cheung, Oakley, et al.
Publicado: (2022)

Zolav(®): a new antibiotic for the treatment of acne [Corrigendum]
Publicado: (2016)

The Role of Imaging in Diagnosing Transthyretin Cardiac Amyloidosis
por: Chaaban, Nourhan, et al.
Publicado: (2021)

Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight
por: Logothetis, Constantine N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ktmbhelj5k5othvj4vhunref1q